Stockholders Approve 50 Million Share Increase, Boosting Potential Dilution

summarizeSummary

Relmada Therapeutics' stockholders approved a 50 million share increase in authorized common stock, significantly expanding the company's capacity for future equity issuance and potential dilution.

check_boxKey Events

• Authorized Shares Increased

  Stockholders approved increasing the number of authorized common stock from 150,000,000 to 200,000,000 shares. This follows the preliminary proxy filing on 2026-04-06.

• Significant Dilution Headroom Created

  With 104,888,223 shares outstanding, the new authorization creates headroom for an additional 95,111,777 shares. If all authorized shares were issued, dilution would be 90.69%.

• Equity Incentive Plan Expanded

  Stockholders approved increasing the shares available for issuance under the 2021 Equity Incentive Plan by 3,000,000 shares, bringing the total to 18,052,942 shares.

• Annual Meeting Results

  The filing also reported the routine election of directors and ratification of independent auditors at the Annual Meeting held on May 27, 2026.

auto_awesomeAnalysis

Relmada Therapeutics' stockholders approved a significant increase in authorized common stock, raising the total from 150 million to 200 million shares. This provides the company with substantial headroom for future equity financing, mergers, or acquisitions, but also introduces the potential for considerable dilution for existing shareholders. Additionally, shares available for the equity incentive plan were increased, further adding to potential dilution.